Alerta

基于人铁蛋白的融合蛋白及其作为多生物活性肽递送系统的用途

Resumen de: WO2025177045A1

The present invention relates to a fusion protein, nanoparticles composed of a plurality of monomers of said fusion protein, nucleic acids encoding said fusion protein, and therapeutic applications thereof. In particular, the fusion protein comprises a first domain based on human ferritin and a second domain conjugated to said first domain and located N-terminally with respect to said first domain, which second domain comprises at least one amino acid sequence of a programmed cell death ligand-1 (PD-L1) binding peptide and/or at least one amino acid sequence of a tumor-penetrating peptide.

具有高亲脂性组分浓度和高亲脂性组分与表面活性剂比率的颗粒、水性分散体和组合物

Resumen de: WO2025160412A1

Particles, aqueous dispersions, and compositions having high lipophilic component (LC) concentrations and high LC to surfactant ratios are described. The particles, aqueous dispersions, and compositions can be used to efficiently deliver active compounds and/or active ingredients through a variety of formulation types.

新型雾化脂质纳米颗粒组合物及其用途

Resumen de: WO2025147528A1

The present invention is based on the surprising discovery that a lipid nanoparticle (LNP) bearing sialic acid residues on the surface can withstand nebulization and maintain its integrity. The invention provides an LNP composition comprising a lipid bearing, or substituted by, a sialic acid (SA) residue such as a ganglioside, a ganglioside derivative, a mimetic, a SA-bearing entity or a combination thereof. The lipid nanoparticles described herein can incorporate nucleic acid molecules, or cargos, withstanding nebulization, and delivering the cargos to the lung via a nebulization-mediated delivery. The present invention also provides methods of using the LNP compositions described herein for pharmaceutical applications. For example, the LNPs provided herein are useful for the treatment of various pulmonary diseases. The LNPs provided herein are also useful for prophylactic applications including vaccines for infectious diseases, allergies, autoimmune diseases and cancer.

用于递送核酸的新型脂质和脂质纳米颗粒制剂

Resumen de: CN113636947A

Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, L1, L2, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

一种葛根芩连汤果胶-壳聚糖纳米粒及制备方法和应用

Resumen de: CN122849189A

本发明属于中药制剂与纳米递送技术领域，具体涉及一种葛根芩连汤果胶‑壳聚糖纳米粒及制备方法和在炎症性肠病相关疾病模型中的应用。采用离子凝胶化法，以壳聚糖为载体，通过带负电的三聚磷酸钠作为交联剂，利用静电相互作用使葛根芩连汤负载于壳聚糖形成纳米粒；再采用果胶对所得纳米粒进行表面包覆，得到葛根芩连汤果胶‑壳聚糖纳米粒。与现有技术相比，本发明工艺温和、步骤简便、重复性好，适用于口服给药及结肠靶向制剂开发。

一种载药磁性过氧化锌纳米颗粒及其制备方法和应用

Resumen de: CN122849187A

本发明提供一种载药磁性过氧化锌复合纳米颗粒及其制备方法和应用，属于癌细胞诊疗剂领域。该制备方法先在碳化铁纳米颗粒表面原位生长过氧化锌，再借助过氧化锌的表面孔隙负载抗癌药物，并利用DSPE‑PEG‑FA进行功能化修饰，以提高其主动靶向和生物安全性。该方法条件温和，步骤简便，所得复合纳米颗粒尺寸均一，稳定性良好，且兼具优异的磁响应性、磁共振成像能力和载药性能，能够显著增强对癌细胞的治疗效果。

一种眼后段药物递送的脂质体、包含脂质体的滴眼液及其应用

Resumen de: CN122849159A

本申请涉及生物医药及创新制剂开发技术领域，具体涉及一种眼后段药物递送的脂质体、包含脂质体的滴眼液及其应用。所述脂质体包括脂质体内核和外层短肽修饰层，所述的脂质体内核包括脂质双层膜，所述短肽包括Gly‑Ser。所述脂质体内核中可以稳定包载治疗剂，将其制备为纳米滴眼液。所述的纳米滴眼液在不影响眼表屏障功能的基础上显著提升治疗剂的跨眼后段穿透性，并且显著提升对于眼病的治疗效果。

一种两性离子聚合物及包含其的脂质组合物和用途

Resumen de: CN122854573A

本公开涉及靶向递送脂质技术领域，具体涉及一种两性离子聚合物及包含其的脂质组合物和用途。本公开提供的靶向脾的两性离子聚合物具有式(I)所示的结构，可用作RNA靶向递送，能够显著增强mRNA药物对于脾靶向效果。

一种负载小分子抗肿瘤药物和光敏剂的功能化仿生纳米粒及其制备方法和应用

Resumen de: CN122849184A

本发明提供了一种负载小分子抗肿瘤药物和光敏剂的功能化仿生纳米粒及其制备方法和应用。该仿生纳米给药系统以TPGS偶联光敏剂Ce6为骨架，包载芫花酯甲（YHC）和黄芪甲苷（AS‑IV），形成YA/Ce6‑TPGS纳米复合物；随后在表面包覆NK细胞膜，构建YA/Ce6‑TPGS@NK功能化仿生靶向递药系统，具有粒径小、载药量和包封率高等特点。系统通过保留NK细胞膜表面的多种蛋白实现对癌细胞的识别与靶向，并降低载体免疫原性，增强循环稳定性，实现精准递送；TPGS‑Ce6载体经光照发挥光动力学杀伤效应，包载的YHC与AS‑IV在肿瘤组织释放，发挥化学抗肿瘤作用，实现化疗与光动力疗法协同抗肿瘤作用。体内外实验表明，其具有显著的抗肿瘤活性和良好生物相容性，并呈现良好的肿瘤靶向性以及潜在的逆转耐药能力。

一种CAR外泌体系统及其制备方法和应用

Resumen de: CN122849194A

本发明涉及一种CAR外泌体系统及其制备方法和应用，CAR‑外泌体系统以外泌体结构为基础，其膜结构上广泛分布有支架蛋白，支架蛋白连接有靶向蛋白，外泌体内包封有抗肿瘤药物；CAR外泌体载药后既具有靶向性，又能有效发挥药物作用实现肿瘤细胞杀伤性；通过各个元件的协同配合，实现高效精准的治疗作用；该CAR‑外泌体系统能够用于制备抗肿瘤药物，改善现有CAR‑T细胞疗法在实体瘤治疗中存在的局限性，且能够作为一种无细胞疗法，规避CAR‑T细胞疗法可能引发的细胞因子风暴等严重毒副作用，安全性更高。

一种基于转谷氨酰胺酶催化交联的工程化细胞、制备方法及其应用

Resumen de: CN122849183A

本发明公开了一种基于转谷氨酰胺酶催化交联的工程化细胞、制备方法及其在免疫性溶血性疾病中的应用；该方法包括：（1）合成化合物I；（2）取细胞悬液，向其中加入化合物I，反应完成后，分离得到化合物I锚定的细胞；（3）合成化合物II和III；（4）向化合物I锚定的细胞悬液中加入化合物II和III，混匀反应后，分离得到聚糖水凝胶包覆的工程化细胞制品。本发明方法制备的工程化细胞制品能够有效掩蔽细胞表面多种抗原表位，用于制备抗原掩蔽型工程化红细胞，使得输注后红细胞在免疫性溶血疾病状态下的体内循环半衰期得以显著延长。

基于香豆素衍生物的声动力治疗仿生纳米颗粒及其抗肿瘤应用

Resumen de: CN122854163A

本发明涉及一种基于香豆素结构的新型有机声敏剂DBCA及其仿生纳米颗粒在肿瘤声动力治疗中的应用。本发明所述声敏剂具有结构简单、原料易得、合成路线短、成本低等优势，在超声作用下能够高效产生ROS，实现对肿瘤细胞的杀伤作用，并具有极低光毒性和良好生物安全性。本发明进一步提供以DSPE‑PEG2000将DBCA包裹形成的纳米颗粒DBCA@PEG，随后利用放疗诱导的肿瘤细胞膜包覆并可联合免疫佐剂获得仿生纳米颗粒DBCA@RM。该仿生结构赋予纳米颗粒同源靶向性，延长肿瘤内驻留时间，同时带有肿瘤相关抗原和固有免疫刺激特性，有助于增强声动力治疗及免疫激活效应。本发明的纳米制剂可应用于肿瘤精准治疗、声动力治疗等领域，具有良好的应用前景。

靶向调节肝脏CD74的细胞外囊泡miRNA在制备糖尿病周围神经病变药物中的应用

Resumen de: CN122849188A

本发明公开了一种靶向调节肝脏CD74的细胞外囊泡miRNA在制备糖尿病周围神经病变（DPN）药物中的应用，属于生物医药技术领域。通过SPECT/CT活体成像首次证实系统给药的间充质基质细胞外囊泡（MSC‑EVs）主要分布于DPN模型肝脏而非外周神经组织，却能显著改善周围神经结构和功能。EVs装载的miR‑24‑3p直接靶向CD74 mRNA 3′UTR，抑制肝巨噬细胞CD74信号通路，减轻系统免疫反应。AAV8介导的肝脏特异性CD74过表达可独立诱发DPN，建立因果证据链。本发明首次提出靶向调节肝脏CD74经肝‑神经免疫轴跨器官治疗DPN的新策略。

一种流感疫苗抗原组合体系及包含该体系的人用流感多价类病毒结构疫苗

Resumen de: CN122849429A

本发明涉及一种流感疫苗抗原组合体系及包含该体系的人用流感多价类病毒结构疫苗，属于生物医药领域，所述的流感疫苗抗原组合体系包括HA重组抗原蛋白和五种mRNA分子，将该组合体系以特定脂质载体包封装载，形成一个外部携带禽流感病毒H5N1的HA蛋白抗原，内部携带人流感病毒A型的H1、H3亚型的HA蛋白和B型HA蛋白编码的mRNA分子、H3N2的NA抗原和禽流感H5N的NP抗原编码mRNA分子的类病毒纳米结构的人用流感多价类病毒结构疫苗。该人用流感多价类病毒结构疫苗能够诱导针对多种流感病毒抗原的广谱免疫反应，包括针对A‑型流感的H1、H3、H5各亚型株的HA抗原、NA和NP抗原及B‑型流感Victoria系的HA抗原的特异性抗体、特异性CTL反应。

一种仿生纳米酶及制备方法与应用

Resumen de: CN122849484A

本发明公开了一种仿生纳米酶及制备方法与应用，一种仿生纳米酶，是以铜/锌双金属沸石咪唑骨架为核心，包覆有聚多巴胺的纳米颗粒，所述铜/锌双金属沸石咪唑骨架简称CZ‑MOF。实验证明，本发明的一种仿生纳米酶能有效清除处于氧化应激状态下的NCM‑460细胞的ROS；能有效抑制炎症性巨噬细胞并促进其向抗炎M2表型极化；能抑制Th17细胞活化、同时促进调节性T细胞（Treg）应答发挥抗炎作用；能促进纳米颗粒在IBD病灶带正电荷的结肠部位靶向富集，从而提升治疗效果。本发明的仿生纳米酶体系稳定，生物相容性良好。本发明的制备方法简单便捷，在制备治疗溃疡性结肠炎药物中的应用。

天然多酚-阳离子多糖自组装纳米颗粒、制备方法和应用

Resumen de: CN122849192A

本发明提供了天然多酚‑阳离子多糖自组装纳米颗粒、制备方法和应用，属于纳米抗炎材料技术领域，所述纳米颗粒由天然多酚与阳离子多糖在水相体系中通过非共价相互作用自组装形成；所述非共价相互作用包括静电作用、氢键作用、π‑π堆积作用和疏水相互作用；所述纳米颗粒呈球形或类球形，粒径为100‑400nm。天然多酚提供抗氧化、抗炎和蛋白结合能力，阳离子多糖提供水分散性、黏附性和载体骨架，二者协同改善传统多酚单分子使用时的稳定性与作用持续性。

HSPE1 RNAi剂及其应用

Resumen de: CN122855458A

本发明属于生物技术领域，涉及HSPE1 RNAi剂及其应用，其中，本发明的RNAi剂能有效稳定敲降结直肠癌细胞中HSPE1的表达水平，可为结直肠癌的个体化治疗提供有效治疗策略。

用于穿透黏液屏障的过氧化氢酶驱动的纳米机器人

Resumen de: WO2025098967A1

The present invention provides a complex for use in delivering a cargo across a mucus barrier, the complex comprising a particle with a surface coated with catalase; and the cargo, wherein the catalase is attached over the whole surface of the particle. The invention also provides a pharmaceutical composition comprising the complex, and the complex or the pharmaceutical composition for use in a therapeutic, prophylactic, and/or diagnostic method.

インフルエンザウイルスＨＡタンパク質をコードするｍＲＮＡを含む組成物およびその使用

Resumen de: ZA202600221B

Provided are an immunogenic composition comprising one or more influenza virus surface hemagglutinin proteins (HA proteins) or an mRNA encoding same, and use thereof for preventing or treating a disease or condition related to influenza virus infection.

脂质化合物

Resumen de: WO2025096940A1

The present invention relates to lipids that include novel triazole, and alkyl- and alkene-substituted amine compounds, intermediates in their synthesis, and uses of such triazole, and alkyl- and alkene-substituted amine compounds in, for example, lipid nanoparticle compositions for drug delivery and cancer treatments.

腫瘍の処置又は予防におけるウイルス３Ｃプロテアーゼの使用

Resumen de: WO2025051164A1

Provided are a use of a virus 3C protease or a nucleic acid molecule encoding the 3C protease in the prevention and/or treatment of a tumor in a subject (e.g., a human), and a use of the virus 3C protease or the nucleic acid molecule encoding the 3C protease in the preparation of a drug for preventing and/or treating a tumor in a subject (e.g., a human).

pH、GSH双响应环糊精纳米粒的制备方法

Resumen de: CN121910693A

The invention relates to a preparation method of pH and GSH dual-response cyclodextrin nanoparticles. The preparation method comprises the following steps: S1, preparing a 10mg/mL lecithin absolute ethyl alcohol solution; s2, a DSPE-PEG 2000-UM206 solution with the concentration of 9 mg/mL is prepared; s3, preparing a water phase; s4, preparing an organic phase; and S5, nano-precipitate self-assembly: in a round-bottom flask, rapidly magnetically stirring the water phase at room temperature, dropwise adding the organic phase into the water phase at a speed of less than 1 mL per minute, and stirring at room temperature for 2 hours. And S6, purification of the nanoparticles: transferring the solution into a 30 kDa ultrafiltration tube, centrifuging for 20 minutes at 4000 * g, and cleaning with PBS for 3 times to obtain the acetalated disulfide bond beta-cyclodextrin dimer nanoparticles. When the pH and GSH double-response cyclodextrin nanoparticle prepared by the preparation method of the pH and GSH double-response cyclodextrin nanoparticle is used for delivering HHT, the pH and GSH double-response cyclodextrin nanoparticle has a sensitive pH/GSH double-response function and an efficient tumor killing effect, has a good treatment effect on OCSCs, can give full play to the tumor killing effect of the HHT, and also can effectively reduce the drug side effect of the HHT.

用于软骨再生的肽及其用途

Resumen de: WO2024122721A1

The present application relates to a peptide having a cartilage regeneration effect and uses thereof, and provides a peptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, a composition for cartilage regeneration comprising the peptide, and a pharmaceutical composition for preventing or treating cartilage diseases, comprising the composition for cartilage regeneration as an active ingredient.

用于软骨再生的肽及其用途

Resumen de: WO2024122723A1

The present application relates to a peptide having a cartilage regeneration effect and uses thereof, and provides a peptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, a composition for cartilage regeneration comprising the peptide, and a pharmaceutical composition for preventing or treating cartilage diseases, comprising the composition for cartilage regeneration as an active ingredient.

LIPIDS AND NANOPARTICLE FORMULATIONS THEREOF

Nº publicación: US20260295080A1 01/10/2026

Solicitante:

ARCTURUS THERAPEUTICS INC [US]
Arcturus Therapeutics, Inc.

Resumen de: US20260295080A1

The present disclosure relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and methods thereof.